These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 16585187

  • 1. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, Gillespie MT.
    Cancer Res; 2006 Apr 01; 66(7):3620-8. PubMed ID: 16585187
    [Abstract] [Full Text] [Related]

  • 2. Osteoprotegerin is expressed in colon carcinoma cells.
    Pettersen I, Bakkelund W, Smedsrød B, Sveinbjørnsson B.
    Anticancer Res; 2005 Apr 01; 25(6B):3809-16. PubMed ID: 16309167
    [Abstract] [Full Text] [Related]

  • 3. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL.
    Cancer Res; 2005 Mar 01; 65(5):1710-8. PubMed ID: 15753366
    [Abstract] [Full Text] [Related]

  • 4. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
    Kitazawa S, Kitazawa R.
    J Pathol; 2002 Oct 01; 198(2):228-36. PubMed ID: 12237883
    [Abstract] [Full Text] [Related]

  • 5. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
    Holen I, Croucher PI, Hamdy FC, Eaton CL.
    Cancer Res; 2002 Mar 15; 62(6):1619-23. PubMed ID: 11912131
    [Abstract] [Full Text] [Related]

  • 6. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
    Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET.
    Cancer Res; 2003 Nov 15; 63(22):7883-90. PubMed ID: 14633717
    [Abstract] [Full Text] [Related]

  • 7. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ.
    Cancer Res; 2001 Jun 01; 61(11):4432-6. PubMed ID: 11389072
    [Abstract] [Full Text] [Related]

  • 8. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
    Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC, Eaton CL.
    J Bone Miner Res; 2004 Oct 01; 19(10):1712-21. PubMed ID: 15355567
    [Abstract] [Full Text] [Related]

  • 9. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A.
    Cancer Res; 2006 May 15; 66(10):5363-70. PubMed ID: 16707463
    [Abstract] [Full Text] [Related]

  • 10. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
    Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL.
    Breast Cancer Res Treat; 2005 Aug 15; 92(3):207-15. PubMed ID: 16155791
    [Abstract] [Full Text] [Related]

  • 11. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 12. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.
    Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, Okamoto M, Sato M, Yu G, Guo C, Shibahala T.
    Clin Cancer Res; 2005 Apr 01; 11(7):2713-9. PubMed ID: 15814653
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
    Yamada N, Tsujimura T, Ueda H, Hayashi S, Ohyama H, Okamura H, Terada N.
    Cytokine; 2005 Aug 21; 31(4):288-97. PubMed ID: 15996478
    [Abstract] [Full Text] [Related]

  • 14. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM, Croucher PI.
    Cancer Res; 2003 Mar 01; 63(5):912-6. PubMed ID: 12615702
    [Abstract] [Full Text] [Related]

  • 15. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG, Lau YS, Itonaga I, Sabokbar A, Athanasou NA.
    J Pathol; 2006 May 01; 209(1):114-20. PubMed ID: 16482498
    [Abstract] [Full Text] [Related]

  • 16. Breast cancer cells interact with osteoblasts to support osteoclast formation.
    Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT.
    Endocrinology; 1999 Oct 01; 140(10):4451-8. PubMed ID: 10499498
    [Abstract] [Full Text] [Related]

  • 17. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ.
    Cancer Res; 2005 Dec 01; 65(23):11001-9. PubMed ID: 16322249
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
    Kubota A, Hasegawa K, Suguro T, Koshihara Y.
    J Rheumatol; 2004 Mar 01; 31(3):426-35. PubMed ID: 14994384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.